Cyclacel Pharmaceuticals, Inc. (CYCC)
-NasdaqGM | Prev Close: | 4.74 |
|---|
| Open: | N/A |
|---|
| Bid: | 4.74 x 300 |
|---|
| Ask: | 5.23 x 400 |
|---|
| 1y Target Est: | 9.50 |
|---|
| Beta: | 1.84 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 2.75 - 8.18 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 376,042 |
|---|
| Market Cap: | 83.97M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.69 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Nasdaq stocks posting largest volume increasesAP(Fri, Sep 20)
- [video] The Top Ten Stocks for Friday, September 20at Bloomberg(Fri, Sep 20)
- On The Fly: After Hours Moversat theflyonthewall.com(Thu, Sep 19)
- AK Steel drops after hours; Tibco surgesat MarketWatch(Thu, Sep 19)
- Cyclacel's Sapacitabine Reported to Have Anti-Tumor Activity Against Ovarian CancerGlobeNewswire(Thu, Sep 19)
- CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other EventsEDGAR Online(Fri, Sep 13)
- With Or Without You Cyclacel Is Going To Riseat Seeking Alpha(Sat, Sep 7)
- CYCLACEL PHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Wed, Aug 21)
- Cyclacel Pharmaceuticals Management Discusses Q2 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, Aug 14)
- CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementEDGAR Online(Wed, Aug 14)
- Cyclacel Reports Second Quarter 2013 Financial ResultsGlobeNewswire(Wed, Aug 14)
- Q2 2013 Cyclacel Pharmaceuticals, Inc. Earnings Release - After Market CloseCCBN(Wed, Aug 14)
- Cyclacel's Seliciclib to be Evaluated in Investigator-Initiated Clinical Study to Treat Rheumatoid ArthritisGlobeNewswire(Mon, Aug 12)
- Cyclacel Pharmaceuticals to Announce Release of Second Quarter 2013 Financial ResultsGlobeNewswire(Thu, Aug 8)
- Should Traders Try To Play The Odds With Cyclacel?at Seeking Alpha(Tue, Aug 6)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 161.79 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.47 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.31 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the development and commercialization of mechanism-targeted drugs to treat human cancers and other serious diseases.
View More